Corbion NV (CRBN) AI Stock Analysis

• Market Cap: €1.07B
• Dividend Yield: 3.45%
• Average Volume (3M): 188.49K
• Price to Earnings (P/E): 19.9
• Beta (1Y): 1.23
• Revenue Growth: -10.78%
• EPS Growth: -24.58%
• Country: NL
• Employees: 2,383
• Sector: Basic Materials
• Sector Strength: 69
• Industry: Chemicals - Specialty
• EPS (TTM): 0.45
• Shares Outstanding: 58,250,310
• 10 Day Avg. Volume: 131,304
• 30 Day Avg. Volume: 188,491
• PEG Ratio: -0.80
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €24.33
• Price Target Upside: 30.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 67 Neutral
• Price Target: €20.50 ▲(10.16%Upside)

Corbion NV shows strong financial performance with improved profitability and a stable balance sheet, although high debt levels warrant caution. Technical analysis indicates mixed signals with potential medium-term strength. Valuation is reasonable with a moderate P/E ratio and attractive dividend yield. These factors contribute to an overall solid stock score.

Corbion NV Business Overview & Revenue Model

Company Description

Corbion NV is a global food and biochemicals company headquartered in the Netherlands. It operates primarily in the biotechnology sector, focusing on producing sustainable ingredient solutions. The company's core products include lactic acid and its derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae-based products. Corbion's solutions serve various industries, including food, pharmaceuticals, and personal care, emphasizing innovation and sustainability.

How the Company Makes Money

Corbion makes money through the sale of its products across two main business segments: Food and Biochemicals. In the Food segment, it generates revenue by providing food ingredient solutions that enhance the quality, safety, and shelf life of food products. This includes emulsifiers, enzymes, and other food additives. The Biochemicals segment generates revenue through the sale of sustainable biobased chemicals, such as lactic acid and its derivatives, which are used in a wide range of applications, including pharmaceuticals, personal care, and industrial products. Corbion's earnings are further supported by strategic partnerships and collaborations that leverage its expertise in biotechnology to develop innovative solutions for its clients.

Corbion NV Financial Statement Overview

Summary

Corbion NV demonstrates strong profitability with an improved net profit margin of 14.9% and efficient operational management, despite a 10.8% revenue decline. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.66 and a high return on equity of 24.9%. Cash flow generation has improved, but the conversion from net income remains moderate with a free cash flow to net income ratio of 0.52.

Income Statement

Corbion NV shows a mixed performance in its income statement. The gross profit margin for the latest year is approximately 24.2%, indicating a strong ability to convert revenue into gross profit. However, the net profit margin has improved significantly to approximately 14.9% from the previous year's 5.0%, driven by increased net income. The revenue growth rate shows a decline of 10.8% from the previous year, suggesting challenges in maintaining top-line growth. The EBIT and EBITDA margins are 6.0% and 13.4% respectively, reflecting efficient operational management despite the revenue decline.

Balance Sheet

The balance sheet presents a stable but leveraged financial position. The debt-to-equity ratio is approximately 0.66, indicating moderate leverage. The return on equity stands high at 24.9%, showcasing effective use of shareholders' capital to generate earnings. The equity ratio is 50%, pointing to a well-balanced asset financing structure through equity and liabilities. However, the high debt levels pose a potential risk in a fluctuating market environment.

Cash Flow

The cash flow statement highlights some concerns. The free cash flow growth has been positive, with an increase from €16.1 million to €99.9 million, indicating improved cash generation capability. However, the operating cash flow to net income ratio of 0.96 suggests less cash generation relative to net income, potentially due to working capital needs or other operational factors. The free cash flow to net income ratio stands at 0.52, showing moderate conversion of net income into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.44B	1.46B	1.07B	986.50M
Gross Profit	312.10M	352.70M	324.30M	265.80M	269.80M
EBITDA	172.00M	198.00M	194.00M	133.10M	154.90M
Net Income	192.20M	72.90M	90.00M	78.30M	73.10M
Balance Sheet
Total Assets	1.55B	1.70B	1.72B	1.36B	1.09B
Cash, Cash Equivalents and Short-Term Investments	49.30M	70.20M	58.20M	42.20M	51.60M
Total Debt	509.20M	785.50M	759.20M	503.20M	335.80M
Total Liabilities	773.80M	1.06B	1.10B	806.50M	578.20M
Stockholders Equity	772.50M	636.20M	625.70M	554.10M	516.00M
Cash Flow
Free Cash Flow	99.90M	16.10M	-182.60M	-122.00M	24.50M
Operating Cash Flow	184.10M	165.40M	53.20M	26.70M	113.40M
Investing Cash Flow	166.00M	-146.80M	-213.30M	-123.70M	-81.30M
Financing Cash Flow	-371.70M	-5.30M	173.90M	85.90M	-23.90M

Corbion NV Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 18.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Neutral. The current price of 18.61 is above the 20-day moving average (MA) of 18.57, below the 50-day MA of 18.96, and below the 200-day MA of 20.50, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 46.89 is Neutral, neither overbought nor oversold. The STOCH value of 56.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NL:CRBN.

Corbion NV Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCD	70 Outperform	€6.59B	22.95	14.13%	1.93%	6.41%	-5.29%
APAM	70 Outperform	€1.96B	8.57	6.92%	7.27%	-1.84%	345.98%
CRBN	67 Neutral	€1.07B	19.90	6.52%	3.45%	-10.78%	-24.58%
AKZA	64 Neutral	€10.21B	21.81	10.15%	5.15%	0.31%	-11.62%
Sector *	62 Neutral	$10.32B	9.99	0.09%	2.85%	2.25%	-33.42%
DSFIR	57 Neutral	€23.65B	94.81		2.81%	20.44%	―
OCI	56 Neutral	€1.56B	58.27		110.57%	―	―